US EditionRigosertib Shows Promise in Epidermolysis Bullosa–Associated Skin Cancer
Summary by Medscape
2 Articles
2 Articles
All
Left
Center
Right
Rigosertib Shows Promise in EB-Associated Skin Cancer
TOPLINE: Rigosertib, a polo-like kinase 1 (PLK1) inhibitor, demonstrated antitumor efficacy in patients with recessive dystrophic epidermolysis bullosa (RDEB) and advanced squamous cell carcinoma (SCC), with an objective response achieved in four of five patients. METHODOLOGY: Researchers conducted an open-label, single-arm phase 2 study in Austria and the United States of five patients with advanced, […] The post Rigosertib Shows Promise in EB-…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
